Share on StockTwits

Research analysts at RBC Capital initiated coverage on shares of Ocular Therapeutix (NASDAQ:OCUL) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $21.00 price target on the stock. RBC Capital’s price target suggests a potential upside of 62.16% from the company’s current price.

Ocular Therapeutix (NASDAQ:OCUL) opened at 14.33 on Tuesday. Ocular Therapeutix has a 1-year low of $11.90 and a 1-year high of $15.249. The stock has a 50-day moving average of $13.32 and a 200-day moving average of $13.32. The company’s market cap is $294.8 million.

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.